GSK to buy US biotech firm IDRx for up to $1.15 billion
Jan 12, 2025 11:18 PM
(Reuters) - British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations,
you may see comments from our Community Managers.